- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04649073
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
June 29, 2023 updated by: Otsuka Pharmaceutical Co., Ltd.
A Multicenter, Uncontrolled, Nonrandomized, Open-Label, Phase 1/2 Trial Investigating the Safety and Efficacy of OPC 415 in MMG49 Antigen-Positive Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
Study Overview
Study Type
Interventional
Enrollment (Estimated)
49
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Drug Information Center
- Phone Number: +81-3-6361-7314
Study Locations
-
-
-
Isehara-shi, Japan
- Recruiting
- Tokai University Hospital
-
Okayama-shi, Japan
- Not yet recruiting
- National Hospital Organization Okayama Medical Center
-
Sendai-shi, Japan
- Recruiting
- Tohoku University Hospital
-
Shibuya-ku, Japan
- Recruiting
- Japanese Red Cross Medical Center
-
Suita-shi, Japan
- Recruiting
- Osaka University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged between 20 and 80 (75 for the phase 1 part) years, both inclusive, at the time of consent
- Patients with a definitive diagnosis of active multiple myeloma
- Patients who have had 2 or more prior regimens (including all proteasome inhibitors, immunomodulators, and anti-CD38 antibody)
- Patients with relapsed and/or refractory Multiple Myeloma
- Patients who are positive for MMG49 antigen
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. Those with an ECOG-PS score of 2 due solely to MM bone lesions can be enrolled
- Patients who are expected to survive for at least 3 months
Exclusion Criteria:
- Patients who are scheduled to receive high-dose chemotherapy in combination with autologous stem cell transplantation as the next treatment.
- Patients who have other active double/multiple cancers
- Patients on continuous and systemic (oral or intravenous) medication with corticosteroids or other immunosuppressive agents
- Patients with graft-versus-host disease that requires treatment.
- Patients who underwent a highly invasive and extensive surgical procedure within 2 weeks.
- Patients who previously underwent allogeneic stem cell transplantation or organ transplantation.
- Patients who underwent autologous stem cell transplantation within 90 days.
- Patients with systemic amyloidosis (except localized amyloidosis without organ derangement) or plasma cell leukemia.
- Patients with prior or current central nerve involvement in MM.
- Patients whose best ever response to MM treatment is PD.
- Patients who previously received gene therapy or cell therapy (except hematopoietic stem cell transplantation).
- Pregnant women, nursing mothers, or women with a positive pregnancy test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OPC-415 (up to 1×10^7cells/kg)
|
OPC-415 (up to 1×10^7cells/kg) On 2 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase1: Dose Limiting Toxicity
Time Frame: Day1~Day28
|
Day1~Day28
|
|
Phase2: Response rate
Time Frame: Day1~Day366
|
The proportion of subjects who achieved partial response or better outcomes by central assessment based on IMWG Uniform Response Criteria for Multiple Myeloma will be calculated.
|
Day1~Day366
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Nobuhito Sanada, Otsuka Pharmaceutical Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2021
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2041
Study Registration Dates
First Submitted
November 24, 2020
First Submitted That Met QC Criteria
November 24, 2020
First Posted (Actual)
December 2, 2020
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 29, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- 415-102-00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
:The focus of this study is a rare disease.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma (MM)
-
Mario BoccadoroActive, not recruiting
-
AbbVieCompletedMultiple Myeloma (MM)United States, Argentina, Australia, Brazil, Canada, Croatia, Czechia, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovenia, Spain, Taiwan, Turkey
-
Acerta Pharma BVAcerta Pharma, LLCCompletedMultiple Myeloma (MM)United States, United Kingdom
-
Fundación de Investigación Biomédica - Hospital...Haematology Service,Unknown
-
Assiut UniversityNot yet recruitingMultiple Myeloma(MM)
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.; Hartford HospitalActive, not recruiting
-
Novartis PharmaceuticalsActive, not recruitingMultiple Myeloma (MM)United States, Italy, Israel, Germany, Japan, Spain, Australia, Norway
-
AbbVieTerminatedCancer | Multiple Myeloma (MM)United States, Australia, France, Israel, Japan, Spain, Taiwan
-
Zhujiang HospitalThe Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaboratorsTerminatedRelapsed/Refractory Multiple Myeloma(MM)China
-
Otsuka Beijing Research InstituteOtsuka Pharmaceutical Co., Ltd.UnknownNon-Hodgkin's Lymphoma(NHL) | Multiple Myeloma(MM)Hong Kong
Clinical Trials on OPC-415
-
Immuneering CorporationRecruitingPancreas Adenocarcinoma | Non-small Cell Lung Cancer | Advanced Solid Tumor (Phase 1) | Malignant Melanoma (Cutaneous)United States
-
Otsuka Pharmaceutical Co., Ltd.RecruitingCardiac Edema (CHF)Japan
-
Eye & ENT Hospital of Fudan UniversityRecruitingOropharynx CarcinomaChina
-
Kyowa Kirin Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaUnited States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophrenia | Psychiatric DisordersUnited States
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed